Trials / Completed
CompletedNCT04053881
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 412 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab pegol | Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection |
Timeline
- Start date
- 2019-08-21
- Primary completion
- 2022-12-02
- Completion
- 2022-12-02
- First posted
- 2019-08-13
- Last updated
- 2023-01-23
Locations
79 sites across 9 countries: Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04053881. Inclusion in this directory is not an endorsement.